Skip to main content

Table 4 Clinical feature analysis of LINC02310 based on TCGA clinical data

From: Identification of LINC02310 as an enhancer in lung adenocarcinoma and investigation of its regulatory network via comprehensive analyses

Clinical features Low High p1 p2
Gender     
 Female 216 60 0.831 0.776
 Male 183 54   
Race     
 American Indian or Alaska native 1 0 0.762 0.745
 Asian 6 1   
 Black or African American 43 9   
 White 300 87   
Age     
 < 55 56 15 0.878 0.803
 ≥ 55 328 95   
TNM-stage     
 I 222 52 0.033 0.027
 II 95 26   
 III 55 29   
 IV 21 5   
T-stage     
 T1/T2 352 92 0.043 0.038
 T3/T4/TX 47 22   
N-stage     
 N0 268 62 0.035 0.035
 N1 71 24   
 N2/N3/NX 60 27   
M-stage     
 M0 265 79 0.726 0.655
 M1 21 4   
 MX 111 29   
Pack-years smoked     
 < 20 49 10 0.389 0.310
   ≥ 20 225 67   
  1. ‘Low’ and ‘high’ represent the number of LADC samples where LINC02310 were low expressed and high expressed, respectively. p1 and p2 are the p-values of Fisher’s accurate test and Pearson’s chi-squared test, respectively